These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 16904377)

  • 1. Clinical experience with recently approved antibiotics.
    Paterson DL
    Curr Opin Pharmacol; 2006 Oct; 6(5):486-90. PubMed ID: 16904377
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of infections caused by resistant Staphylococcus aureus.
    Anstead GM; Quinones-Nazario G; Lewis JS
    Methods Mol Biol; 2007; 391():227-58. PubMed ID: 18025681
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacologic treatment options for nosocomial pneumonia involving methicillin-resistant Staphylococcus aureus.
    Maclayton DO; Hall RG
    Ann Pharmacother; 2007 Feb; 41(2):235-44. PubMed ID: 17299012
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New antibiotics for the treatment of severe staphylococcal infection in the critically ill patient.
    Schmidt-Ioanas M; de Roux A; Lode H
    Curr Opin Crit Care; 2005 Oct; 11(5):481-6. PubMed ID: 16175036
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New treatments for methicillin-resistant Staphylococcus aureus.
    Stryjewski ME; Corey GR
    Curr Opin Crit Care; 2009 Oct; 15(5):403-12. PubMed ID: 19561492
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparison of available and investigational antibiotics for complicated skin infections and treatment-resistant Staphylococcus aureus and enterococcus.
    Scheinfeld N
    J Drugs Dermatol; 2007 Jan; 6(1):97-103. PubMed ID: 17373167
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent advances in the treatment of infections due to resistant Staphylococcus aureus.
    Anstead GM; Owens AD
    Curr Opin Infect Dis; 2004 Dec; 17(6):549-55. PubMed ID: 15640709
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tigecycline: first of a new class of antimicrobial agents.
    Rose WE; Rybak MJ
    Pharmacotherapy; 2006 Aug; 26(8):1099-110. PubMed ID: 16863487
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current and new antimicrobial agents.
    Eliopoulos GM
    Am Heart J; 2004 Apr; 147(4):587-92. PubMed ID: 15077072
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Susceptibility to daptomycin, quinupristin-dalfopristin and linezolid and some other antibiotics in clinical isolates of methicillin resistant and methicillin sensitive S.aureus from the Oslo area.
    Jørgen B; Merckoll P; Melby KK
    Scand J Infect Dis; 2007; 39(11-12):1059-62. PubMed ID: 17852934
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Staphylococcus aureus and antibiotic resistance].
    Sancak B
    Mikrobiyol Bul; 2011 Jul; 45(3):565-76. PubMed ID: 21935792
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative activity of the new lipoglycopeptide telavancin in the presence and absence of serum against 50 glycopeptide non-susceptible staphylococci and three vancomycin-resistant Staphylococcus aureus.
    Leuthner KD; Cheung CM; Rybak MJ
    J Antimicrob Chemother; 2006 Aug; 58(2):338-43. PubMed ID: 16787952
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [New anti-Gram+antibiotics: which role in infective endocarditis?].
    Makinson A; Le Moing V
    Ann Cardiol Angeiol (Paris); 2008 Apr; 57(2):88-92. PubMed ID: 18395180
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The antimicrobial armamentarium: evaluating current and future treatment options.
    Bosso JA
    Pharmacotherapy; 2005 Oct; 25(10 Pt 2):55S-62S. PubMed ID: 16178676
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibiotics for gram-positive bacterial infections: vancomycin, teicoplanin, quinupristin/dalfopristin, oxazolidinones, daptomycin, dalbavancin, and telavancin.
    Nailor MD; Sobel JD
    Infect Dis Clin North Am; 2009 Dec; 23(4):965-82, ix. PubMed ID: 19909893
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of current agents used in the treatment of Gram-positive infections and the consequences of resistance.
    Segreti J
    Clin Microbiol Infect; 2005 May; 11 Suppl 3():29-35. PubMed ID: 15811022
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic challenges in the era of antibiotic resistance.
    Lee C
    Int J Antimicrob Agents; 2008 Dec; 32 Suppl 4():S197-9. PubMed ID: 19134519
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bactericidal agents in the treatment of MRSA infections--the potential role of daptomycin.
    French GL
    J Antimicrob Chemother; 2006 Dec; 58(6):1107-17. PubMed ID: 17040922
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tigecycline: a new glycylcycline for treatment of serious infections.
    Noskin GA
    Clin Infect Dis; 2005 Sep; 41 Suppl 5():S303-14. PubMed ID: 16080069
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibiotics for gram-positive bacterial infections: vancomycin, quinupristin-dalfopristin, linezolid, and daptomycin.
    Lundstrom TS; Sobel JD
    Infect Dis Clin North Am; 2004 Sep; 18(3):651-68, x. PubMed ID: 15308280
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.